Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GBT
Previous Symbol
CUSIPN/A
Phone650-741-7700
Debt
Debt-to-Equity RatioN/A
Current Ratio14.57
Quick Ratio14.57
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.93 per share
Price / Book6.24
Profitability
EPS (Most Recent Fiscal Year)($2.76)
Net Income$-117,020,000.00
Net MarginsN/A
Return on Equity-36.23%
Return on Assets-33.59%
Miscellaneous
Employees147
Outstanding Shares52,230,000
Market Cap$2.23 billion
OptionableOptionable
Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions
What is Global Blood Therapeutics' stock symbol?
Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."
How were Global Blood Therapeutics' earnings last quarter?
Global Blood Therapeutics Inc (NASDAQ:GBT) issued its quarterly earnings results on Tuesday, November, 6th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.02. During the same quarter in the previous year, the company posted ($0.66) EPS. View Global Blood Therapeutics' Earnings History.
When is Global Blood Therapeutics' next earnings date?
What price target have analysts set for GBT?
14 Wall Street analysts have issued twelve-month price targets for Global Blood Therapeutics' stock. Their predictions range from $61.00 to $150.00. On average, they expect Global Blood Therapeutics' share price to reach $86.3571 in the next twelve months. This suggests a possible upside of 99.8% from the stock's current price. View Analyst Price Targets for Global Blood Therapeutics.
What is the consensus analysts' recommendation for Global Blood Therapeutics?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 1 hold rating and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Global Blood Therapeutics.
What are Wall Street analysts saying about Global Blood Therapeutics stock?
Here are some recent quotes from research analysts about Global Blood Therapeutics stock:
- 1. William Blair analysts commented, "We note that the company has enrolled another roughly 118 patients with the goal of seeking accelerated approval. As noted in Tuesday’s press release, management expects to provide a regulatory update by the end of the year ." (11/7/2018)
- 2. Cantor Fitzgerald analysts commented, "Based on the existing clinical data, we believe voxelotor offers a compelling treatment option in SCD that lacks disease-modifying therapies. $96 price target is based on the combination of our estimate of the NPV of future cash flows from voxelotor in SCD, worth approximately $4.6 billion ($88/share), and our estimate of YE cash of $440 million ($8/share)." (10/17/2018)
- 3. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (10/10/2018)
- 4. HC Wainwright analysts commented, "We continue to expect voxelotor in conjunction with HU to become the standard-of-care, especially in younger patients, which could make these patients asymptomatic much like SCD-trait subjects. Our Buy rating and price target of $125 are based on a DCF analysis, derived using a beta of 1.40, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.9%, and tax rate of 15% beginning in FY 2024. We estimate approximately 70K patients in U.S., 42K patients in the $$60K (increased from $75K and $50K) U.S." (8/23/2018)
- 5. JPMorgan Chase & Co. analysts commented, "GBT reported 2Q results via press release (no conference call, as usual) that focused on lead program voxelotor in sickle cell disease. The print overall was uneventful as we await a regulatory update at some point in 2H18 on the potential for an accelerated approval filing. The other key event remaining this year is the presentation of detailed data from Part A of the Phase 3 HOPE trial anticipated at ASH in December." (8/5/2018)
Has Global Blood Therapeutics been receiving favorable news coverage?
News stories about GBT stock have trended neutral recently, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Global Blood Therapeutics earned a media sentiment score of 0.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the immediate future.
Who are some of Global Blood Therapeutics' key competitors?
Some companies that are related to Global Blood Therapeutics include Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE), Bausch Health Companies (BHC), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Alkermes (ALKS), Amarin (AMRN), Catalent (CTLT), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE) and Amneal Pharmaceuticals (AMRX).
Who are Global Blood Therapeutics' key executives?
Global Blood Therapeutics' management team includes the folowing people:
- Dr. Ted W. Love, Pres, CEO & Director (Age 59)
- Dr. Charles J. Homcy, Founder, Advisor & Director (Age 70)
- Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 56)
- Mr. Peter Radovich, Sr. VP of Operations (Age 40)
- Dr. Hing Sham, Sr. VP of Research (Age 66)
When did Global Blood Therapeutics IPO?
(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.
Who are Global Blood Therapeutics' major shareholders?
Global Blood Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Perceptive Advisors LLC (9.86%), Vanguard Group Inc. (8.05%), BlackRock Inc. (8.04%), Janus Henderson Group PLC (6.28%) and Franklin Resources Inc. (1.65%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Jung Choi, Kevin P Starr, Lesley Ann Calhoun, Perceptive Advisors Llc, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.
Which major investors are selling Global Blood Therapeutics stock?
GBT stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Los Angeles Capital Management & Equity Research Inc., Essex Investment Management Co. LLC, Congress Asset Management Co. MA, TIAA CREF Investment Management LLC, Virtus ETF Advisers LLC, Credit Suisse AG and Allianz Asset Management GmbH. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Deval L Patrick, Jung Choi, Lesley Ann Calhoun and Peter Radovich. View Insider Buying and Selling for Global Blood Therapeutics.
Which major investors are buying Global Blood Therapeutics stock?
GBT stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, PointState Capital LP, Perceptive Advisors LLC, Brown Advisory Inc., Nexthera Capital LP, Franklin Resources Inc., Vanguard Group Inc. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Global Blood Therapeutics.
How do I buy shares of Global Blood Therapeutics?
Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Global Blood Therapeutics' stock price today?
One share of GBT stock can currently be purchased for approximately $43.23.
How big of a company is Global Blood Therapeutics?
Global Blood Therapeutics has a market capitalization of $2.23 billion. The company earns $-117,020,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Global Blood Therapeutics employs 147 workers across the globe.
What is Global Blood Therapeutics' official website?
How can I contact Global Blood Therapeutics?
Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]
MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
